Luigi Schips

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1147133/publications.pdf

Version: 2024-02-01

71102 118850 5,153 164 41 62 citations h-index g-index papers 166 166 166 4752 times ranked docs citations citing authors all docs

#	Article	IF	CITATIONS
1	Is offâ€clamp robotâ€assisted partial nephrectomy beneficial for renal function? Data from the CLOCK trial. BJU International, 2022, 129, 217-224.	2.5	53
2	Simultaneous robotic partial nephrectomy for bilateral renal masses. World Journal of Urology, 2022, 40, 1005-1010.	2.2	4
3	Active surveillance for small renal masses in elderly patients does not increase overall mortality rates compared to primary intervention: a propensity score weighted analysis. Minerva Urology and Nephrology, 2022, 73, .	2.5	4
4	Association of statin use and oncological outcomes in patients with first diagnosis of T1 high grade non-muscle invasive urothelial bladder cancer: results from a multicenter study. Minerva Urology and Nephrology, 2022, 73, .	2. 5	4
5	Prediction of significant renal function decline after open, laparoscopic, and robotic partial nephrectomy: External validation of the Martini's nomogram on the RECORD2 project cohort. International Journal of Urology, 2022, 29, 525-532.	1.0	9
6	Conspicuity and muscle-invasiveness assessment for bladder cancer using VI-RADS: a multi-reader, contrast-free MRI study to determine optimal b-values for diffusion-weighted imaging. Abdominal Radiology, 2022, 47, 1862-1872.	2.1	4
7	Cross-analysis of two randomized controlled trials to compare pure versus robot-assisted laparoscopic approach during off-clamp partial nephrectomy. Minerva Urology and Nephrology, 2022, 74, 5-10.	2.5	6
8	Real-world experience of abiraterone acetate plus prednisone in chemotherapy-naive patients with metastatic castration-resistant prostate cancer: long-term results of the prospective ABItude study. ESMO Open, 2022, 7, 100431.	4.5	1
9	Selective renal artery clamp during robot assisted partial nephrectomy: The use of indocyanine green. Urology Video Journal, 2022, 14, 100148.	0.2	О
10	Potential benefit of lymph node dissection during radical nephrectomy for kidney cancer: A review and critical analysis of current literature. Asian Journal of Urology, 2022, 9, 215-226.	1.2	4
11	Micro-RNAs Predict Response to Systemic Treatments in Metastatic Renal Cell Carcinoma Patients: Results from a Systematic Review of the Literature. Biomedicines, 2022, 10, 1287.	3.2	10
12	Bladder cancer: do we need contrast injection for MRI assessment of muscle invasion? A prospective multi-reader VI-RADS approach. European Radiology, 2021, 31, 3874-3883.	4. 5	34
13	Retroperitoneal extension of massive ulcerated testicular seminoma through the inguinal canal: A case report. Archivio Italiano Di Urologia Andrologia, 2021, 93, 64-67.	0.8	1
14	Biomarkers for Renal Cell Carcinoma Recurrence: State of the Art. Current Urology Reports, 2021, 22, 31.	2.2	23
15	Conservative treatment of upper urinary tract carcinoma in patients with imperative indications. Minerva Urology and Nephrology, 2021, 73, 245-252.	2.5	11
16	Efficacy and safety of intravesical fibrin glue instillation for management of patients with refractory hemorrhagic cystitis: 12-months results. A promising therapy for hemorrhagic cystitis. Archivio Italiano Di Urologia Andrologia, 2021, 93, 200-205.	0.8	1
17	Management of local recurrence after radical nephrectomy: surgical removal with or without systemic treatment is still the gold standard. Results from a multicenter international cohort. International Urology and Nephrology, 2021, 53, 2273-2280.	1.4	7
18	Enzalutamide in patients with castration-resistant prostate cancer: retrospective, multicenter, real life study. Minerva Urology and Nephrology, 2021, 73, 489-497.	2.5	7

#	Article	IF	Citations
19	Potential prognostic value of miRNAs as biomarker for progression and recurrence after nephrectomy in renal cell carcinoma: a literature review. Diagnosis, 2021, .	1.9	5
20	The Impact of SARS-CoV-2 Pandemic on Time to Primary, Secondary Resection and Adjuvant Intravesical Therapy in Patients with High-Risk Non-Muscle Invasive Bladder Cancer: A Retrospective Multi-Institutional Cohort Analysis. Cancers, 2021, 13, 5276.	3.7	21
21	Trifecta Outcomes of Partial Nephrectomy in Patients Over 75 Years Old: Analysis of the REnal SURGery in Elderly (RESURGE) Group. European Urology Focus, 2020, 6, 982-990.	3.1	20
22	Partial versus radical nephrectomy in very elderly patients: a propensity score analysis of surgical, functional and oncologic outcomes (RESURGE project). World Journal of Urology, 2020, 38, 151-158.	2.2	23
23	GreenLight Photoselective Vaporization of the Prostate: One Laser for Different Prostate Sizes. Journal of Endourology, 2020, 34, 54-62.	2.1	15
24	Managing lines of therapy in castration-resistant prostate cancer: real-life snapshot from a multicenter cohort. World Journal of Urology, 2020, 38, 1757-1764.	2.2	6
25	Safety of on- vs off-clamp robotic partial nephrectomy: per-protocol analysis from the data of the CLOCK randomized trial. World Journal of Urology, 2020, 38, 1101-1108.	2.2	35
26	External validation of Cormio nomogram for predicting all prostate cancers and clinically significant prostate cancers. World Journal of Urology, 2020, 38, 2555-2561.	2.2	5
27	Effectiveness of abiraterone acetate plus prednisone in chemotherapy-na \tilde{A} -ve patients with metastatic castration-resistant prostate cancer in a large prospective real-world cohort: the ABItude study. Therapeutic Advances in Medical Oncology, 2020, 12, 175883592096872.	3.2	6
28	Radical penectomy, a compromise for life: results from the PECAD study. Translational Andrology and Urology, 2020, 9, 1306-1313.	1.4	9
29	Could Bladder Multiparametric MRI Be Introduced in Routine Clinical Practice? Role of the New VI-RADS Score: Results From a Prospective Study. Clinical Genitourinary Cancer, 2020, 18, 409-415.e1.	1.9	36
30	Effect of Obesity and Overweight Status on Complications and Survival After Minimally Invasive Kidney Surgery in Patients with Clinical T ₂₋₄ Renal Masses. Journal of Endourology, 2020, 34, 289-297.	2.1	9
31	Robotic partial nephrectomy vs minimally invasive radical nephrectomy for clinical T2a renal mass: a propensity scoreâ€matched comparison from the ROSULA (Robotic Surgery for Large Renal Mass) Collaborative Group. BJU International, 2020, 126, 114-123.	2.5	42
32	New Antiandrogen Compounds Compared to Docetaxel for Metastatic Hormone Sensitive Prostate Cancer: Results from a Network Meta-Analysis. Journal of Urology, 2020, 203, 751-759.	0.4	44
33	How Targeted Therapy Influence Renal Surgery for Renal Cell Carcinoma. Current Drug Targets, 2020, 21, 1550-1557.	2.1	3
34	Persistence and adherence to androgen deprivation therapy in men with prostate cancer: an administrative database study. Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology, 2020, 72, 615-621.	3.9	12
35	Operative profile, safety and functional outcomes after GreenLight laser prostate surgery: results from a 12 months follow-up multicenter Italian cohort analyses. Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology, 2020, 72, 622-628.	3.9	12
36	Management of erectile dysfunction following robot-assisted radical prostatectomy: a systematic review. Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology, 2020, 72, 543-554.	3.9	11

#	Article	IF	Citations
37	A drug safety evaluation of abiraterone acetate in the treatment of prostate cancer. Expert Opinion on Drug Safety, 2019, 18, 759-767.	2.4	3
38	Major Acute Cardiovascular Events After Transurethral Prostate Surgery: A Population-based Analysis. Urology, 2019, 131, 196-203.	1.0	6
39	Comprehensive analysis of in-hospital delirium after major surgical oncology procedures. Canadian Urological Association Journal, 2019, 14, E84-E93.	0.6	5
40	Adherence to the EAU guidelines on Penile Cancer Treatment: European, multicentre, retrospective study. Journal of Cancer Research and Clinical Oncology, 2019, 145, 921-926.	2.5	18
41	Outcomes of Partial and Radical Nephrectomy in Octogenarians – A Multicenter International Study (Resurge). Urology, 2019, 129, 139-145.	1.0	9
42	Robotic versus laparoscopic radical nephrectomy: a large multi-institutional analysis (ROSULA) Tj ETQq0 0 0 rgBT	- Qverlock	R 10 Tf 50 54
43	Adherence to EAU guidelines on penile cancer translates into better outcomes: a multicenter international study. World Journal of Urology, 2019, 37, 1649-1657.	2.2	27
44	Physical Activity as a Protective Factor for Lower Urinary Tract Symptoms in Male Patients: A Prospective Cohort Analysis. Urology, 2019, 125, 163-168.	1.0	13
45	Comparison of Partial Versus Radical Nephrectomy Effect on Other-cause Mortality, Cancer-specific Mortality, and 30-day Mortality in Patients Older Than 75 Years. European Urology Focus, 2019, 5, 467-473.	3.1	21
46	Survival after Cytoreductive Nephrectomy in Metastatic Non-clear Cell Renal Cell Carcinoma Patients: A Population-based Study. European Urology Focus, 2019, 5, 488-496.	3.1	41
47	Predictors of the Transition from Off to On Clamp Approach during Ongoing Robotic Partial Nephrectomy: Data from the CLOCK Randomized Clinical Trial. Journal of Urology, 2019, 202, 62-68.	0.4	31
48	Adherence to hormonal deprivation therapy in prostate cancer in clinical practice: a retrospective, single-center study. Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology, 2019, 71, 181-184.	3.9	8
49	The role of vascular clamping during robot-assisted partial nephrectomy for localized renal cancer: rationale and design of the CLOCK randomized phase III study. Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology, 2019, 71, 96-100.	3.9	22
50	Reply by Authors. Journal of Urology, 2019, 202, 68-68.	0.4	0
51	Trifecta and Pentafecta Rates After Robotic Assisted Partial Nephrectomy: Comparative Study of Patients with Renal Masses <4 and ≥4 cm. Journal of Laparoendoscopic and Advanced Surgical Techniques - Part A, 2018, 28, 799-803.	1.0	15
52	Standard vs. anatomical 180-W GreenLight laser photoselective vaporization of the prostate: a propensity score analysis. World Journal of Urology, 2018, 36, 91-97.	2.2	9
53	The impact of lymph node dissection and positive lymph nodes on cancerâ€specific mortality in contemporary <scp>pT</scp> _{2â€3} nonâ€metastatic renal cell carcinoma treated with radical nephrectomy. BJU International, 2018, 121, 383-392.	2.5	30
54	New insight in penile cancer. Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology, 2018, 70, 559-569.	3.9	20

#	Article	IF	CITATIONS
55	Onabotulinumtoxin-A improves health status and urinary symptoms in subjects with refractory overactive bladder: Real-life experience. Urologia, 2018, 85, 163-168.	0.7	2
56	Abiraterone acetate for early stage metastatic prostate cancer: patient selection and special considerations. Therapeutics and Clinical Risk Management, 2018, Volume 14, 2341-2347.	2.0	11
57	Development and Internal Validation of Novel Nomograms Based on Benign Prostatic Obstruction-Related Parameters to Predict the Risk of Prostate Cancer at First Prostate Biopsy. Frontiers in Oncology, 2018, 8, 438.	2.8	29
58	Comparison Between Thulium Laser VapoEnucleation and GreenLight Laser Photoselective Vaporization of the Prostate in Real-Life Setting: Propensity Score Analysis. Urology, 2018, 121, 147-152.	1.0	14
59	The Surgical Experience Influences the Safety and Efficacy of Photovaporization of Prostate with 180-W XPS GreenLight Laser: Comparison Between Novices <i>vs</i> Journal of Endourology, 2018, 32, 1071-1077.	2.1	8
60	Perioperative major acute cardiovascular events after 180-W GreenLight laser photoselective vaporization of the prostate. International Urology and Nephrology, 2018, 50, 1955-1962.	1.4	8
61	Effect of African-American race on cancer specific mortality differs according to clear cell vs. non-clear cell histologic subtype in metastatic renal cell carcinoma. Cancer Epidemiology, 2018, 54, 112-118.	1.9	13
62	Outcomes of Robot-assisted Partial Nephrectomy for Clinical T2 Renal Tumors: A Multicenter Analysis (ROSULA Collaborative Group). European Urology, 2018, 74, 226-232.	1.9	109
63	The Effect of Institution Teaching Status on Perioperative Outcomes After Robotic Partial or Radical Nephrectomy. Journal of Endourology, 2018, 32, 621-629.	2.1	8
64	Abiraterone in chemotherapy-naive patients with metastatic castration-resistant prostate cancer: a systematic review of â€~real-life' studies. Therapeutic Advances in Urology, 2018, 10, 305-315.	2.0	16
65	Monocenter Experience with 532 Nm-Laser Photoselective-Vaporization of the Prostate by GreenLight XPS™ Laser: Is It Really an Endourological Joker Card?. Surgical Technology International, 2018, 32, 164-172.	0.2	0
66	High Neutrophil-to-lymphocyte Ratio as Prognostic Factor in Patients Affected by Upper Tract Urothelial Cancer: A Systematic Review and Ameta-analysis. Clinical Genitourinary Cancer, 2017, 15, 343-349.e1.	1.9	29
67	Impact of diagnostic ureteroscopy on intravesical recurrence in patients undergoing radical nephroureterectomy for upper tract urothelial cancer: a systematic review and metaâ€analysis. BJU International, 2017, 120, 313-319.	2.5	98
68	Abiraterone Acetate for Treatment of Metastatic Castration-resistant Prostate Cancer in Chemotherapy-naive Patients: An Italian Analysis of Patients' Satisfaction. Clinical Genitourinary Cancer, 2017, 15, 520-525.	1.9	11
69	RIRS in the elderly: Is it feasible and safe?. International Journal of Surgery, 2017, 42, 147-151.	2.7	21
70	Marital status and gender affect stage, tumor grade, treatment type and cancer specific mortality in T1 \hat{a} \in "2 N0 M0 renal cell carcinoma. World Journal of Urology, 2017, 35, 1899-1905.	2.2	28
71	Survival of metastatic renal cell carcinoma patients continues to improve over time, even in targeted therapy era. International Urology and Nephrology, 2017, 49, 2143-2149.	1.4	36
72	Bladder Neck Contracture After Endoscopic Surgery for Benign Prostatic Obstruction: Incidence, Treatment, and Outcomes. Current Urology Reports, 2017, 18, 79.	2.2	29

#	Article	IF	CITATIONS
73	The surgical experience influences the safety of retrograde intrarenal surgery for kidney stones: a propensity score analysis. Urolithiasis, 2017, 45, 387-392.	2.0	27
74	Bladder neck contracture after surgery for benign prostatic obstruction. Minerva Urology and Nephrology, 2017, 69, 133-143.	2.5	20
75	Life-threatening complications after ureteroscopy for urinary stones: survey and systematic literature review. Minerva Urology and Nephrology, 2017, 69, 421-431.	2.5	35
76	Safety and efficacy of abiraterone acetate in chemotherapy-naive patients with metastatic castration-resistant prostate cancer: an Italian multicenter "real life―study. BMC Cancer, 2017, 17, 753.	2.6	24
77	Leydig Cell Tumor in a 53-Year-Old Patient with Gynecomastia and Gynecodynia: A Case Report and Literature Review. International Journal of Cancer Management, 2017, 10, .	0.4	0
78	A prospective multicenter European study on flexible ureterorenoscopy for the management of renal stone. International Braz J Urol: Official Journal of the Brazilian Society of Urology, 2016, 42, 479-486.	1.5	31
79	Intraoperative presentation of Bochdalek's hernia in an adult during robotic-assisted partial nephrectomy: An uncommon situation and literature review. Archivio Italiano Di Urologia Andrologia, 2016, 87, 327.	0.8	5
80	Work up of Incidental Adrenal Mass: State of the Art. Urologia, 2016, 83, 179-185.	0.7	5
81	The Clinical Use of the Neutrophil to Lymphocyte Ratio (NLR) in Urothelial Cancer: AÂSystematic Review. Clinical Genitourinary Cancer, 2016, 14, 473-484.	1.9	84
82	Impact of novel techniques on minimally invasive adrenal surgery: trends and outcomes from a contemporary international large series in urology. World Journal of Urology, 2016, 34, 1473-1479.	2.2	19
83	Infective complications after retrograde intrarenal surgery: a new standardized classification system. International Urology and Nephrology, 2016, 48, 1757-1762.	1.4	62
84	Mortality and flexible ureteroscopy: analysis of six cases. World Journal of Urology, 2016, 34, 305-310.	2.2	101
85	SOX2 boosts major tumor progression genes in prostate cancer and is a functional biomarker of lymph node metastasis. Oncotarget, 2016, 7, 12372-12385.	1.8	49
86	Patient's adherence on pharmacological therapy for benign prostatic hyperplasia (BPH)-associated lower urinary tract symptoms (LUTS) is different: is combination therapy better than monotherapy?. BMC Urology, 2015, 15, 96.	1.4	63
87	Editorial Comment to Nomograms incorporating serum <scp>C</scp> â€reactive protein effectively predict mortality before and after surgical treatment of renal cell carcinoma. International Journal of Urology, 2015, 22, 270-270.	1.0	0
88	Giant renal artery aneurysm: A case report. Archivio Italiano Di Urologia Andrologia, 2015, 87, 169.	0.8	3
89	Drug Adherence and Clinical Outcomes for Patients Under Pharmacological Therapy for Lower Urinary Tract Symptoms Related to Benign Prostatic Hyperplasia: Population-based Cohort Study. European Urology, 2015, 68, 418-425.	1.9	147
90	Evaluation of the Prognostic Significance of Perirenal Fat Invasion and Tumor Size in Patients with pT1–pT3a Localized Renal Cell Carcinoma in a Comprehensive Multicenter Study of the CORONA project. Can We Improve Prognostic Discrimination for Patients with Stage pT3a tumors?. European Urology, 2015, 67, 943-951.	1.9	45

#	Article	IF	Citations
91	Safety, efficacy and reliability of 180-W GreenLight laser technology for prostate vaporization: review of the literature. World Journal of Urology, 2015, 33, 599-607.	2.2	24
92	Efficacy and safety of dutasteride for the treatment of symptomatic benign prostatic hyperplasia (BPH): a systematic review and meta-analysis. World Journal of Urology, 2015, 33, 441-442.	2.2	5
93	Current Pharmacological Treatment for Male LUTS due to BPH: Dutasteride or Finasteride?. Current Drug Targets, 2015, 16, 1165-1171.	2.1	28
94	The R.E.N.A.L. Nephrometric Nomogram Cannot Accurately Predict Malignancy or Aggressiveness of Small Renal Masses Amenable to Partial Nephrectomy. Clinical Genitourinary Cancer, 2014, 12, 366-372.	1.9	21
95	Do Young Patients with Renal Cell Carcinoma Feature a Distinct Outcome after Surgery? A Comparative Analysis of Patient Age Based on the Multinational CORONA Database. Journal of Urology, 2014, 191, 310-315.	0.4	20
96	Analysis of oncological outcomes and renal function after laparoendoscopic singleâ€site (<scp>LESS</scp>) partial nephrectomy: a multiâ€institutional outcome analysis. BJU International, 2014, 113, 266-274.	2.5	23
97	Results of a comparative study analyzing octogenarians with renal cell carcinoma in a competing risk analysis with patients in the seventh decade of life1Matthias May and Luca Cindolo have equally contributed to first authorship.2Sabine Brookman-May and Petros Sountoulides have equally contributed to last authorship Urologic Oncology: Seminars and Original Investigations, 2014, 32,	1.6	8
98	Actual medical management of lower urinary tract symptoms related to benign prostatic hyperplasia: temporal trends of prescription and hospitalization rates over 5Âyears in a large population of Italian men. International Urology and Nephrology, 2014, 46, 695-701.	1.4	28
99	Splenogonadal fusion mimicking a testis tumor. Journal of Postgraduate Medicine, 2014, 60, 202-204.	0.4	12
100	Gender differences in clinicopathological features and survival in surgically treated patients with renal cell carcinoma: an analysis of the multicenter CORONA database. World Journal of Urology, 2013, 31, 1073-1080.	2.2	39
101	Abdominal obesity as risk factor for prostate cancer diagnosis and high grade disease: A prospective multicenter Italian cohort study. Urologic Oncology: Seminars and Original Investigations, 2013, 31, 997-1002.	1.6	50
102	Features Associated with Recurrence Beyond 5 Years After Nephrectomy and Nephron-Sparing Surgery for Renal Cell Carcinoma: Development and Internal Validation of a Risk Model (PRELANE score) to Predict Late Recurrence Based on a Large Multicenter Database (CORONA/SATURN Project). European Urology, 2013, 64, 472-477.	1.9	91
103	Laparoendoscopic Single-site Partial Nephrectomy Without Ischemia for Very Small, Exophytic Renal Masses: Surgical Details and Functional Outcomes. European Urology, 2013, 63, 759-765.	1.9	14
104	Laparoendoscopic Single-site Partial Nephrectomy: A Multi-institutional Outcome Analysis. European Urology, 2013, 64, 314-322.	1.9	46
105	Prognostic Effect of Sarcomatoid Dedifferentiation in Patients With Surgically Treated Renal Cell Carcinoma: A Matched-Pair Analysis. Clinical Genitourinary Cancer, 2013, 11, 465-470.	1.9	10
106	The effects of dutasteride and finasteride on BPH-related hospitalization, surgery and prostate cancer diagnosis: a record-linkage analysis. World Journal of Urology, 2013, 31, 665-671.	2.2	10
107	Assessing the accuracy and generalizability of the preoperative and postoperative <scp>K</scp> arakiewicz nomograms for renal cell carcinoma: results from a multicentre <scp>E</scp> uropean and <scp>US</scp> study. BJU International, 2013, 112, 578-584.	2.5	18
108	Clinical effects and economical impact of dutasteride and finasteride therapy in Italian men with LUTS. Archivio Italiano Di Urologia Andrologia, 2013, 85, 200.	0.8	4

#	Article	IF	Citations
109	Age at diagnosis is a determinant factor of renal cell carcinoma– specific survival in patients treated with nephrectomy. Canadian Urological Association Journal, 2013, 2, 610.	0.6	40
110	Laparoendoscopic single site (LESS) adrenalectomy: Technique and outcomes. World Journal of Urology, 2012, 30, 597-604.	2.2	42
111	Urological Laparoendoscopic Single Site Surgery: Multi-Institutional Analysis of Risk Factors for Conversion and Postoperative Complications. Journal of Urology, 2012, 187, 1989-1994.	0.4	48
112	A comparison of hexaminolevulinate (Hexvix \hat{A}^{\otimes}) fluorescence cystoscopy and white-light cystoscopy for detection of bladder cancer: results of the HeRo observational study. Surgical Endoscopy and Other Interventional Techniques, 2012, 26, 3634-3641.	2.4	61
113	Laparoendoscopic Single-Site Upper Urinary Tract Surgery: Assessment of Postoperative Complications and Analysis of Risk Factors. European Urology, 2012, 61, 510-516.	1.9	54
114	Mini-laparoscopy, laparoendoscopic single-site surgery and natural orifice transluminal endoscopic surgery-assisted laparoscopy: novice surgeons' performance and perception in a porcine nephrectomy model. BJU International, 2012, 110, E991-E996.	2.5	16
115	Nephron sparing LESS: technique and review of the current literature. Archivos Espanoles De Urologia, 2012, 65, 303-10.	0.2	10
116	Laparoendoscopic Single-Site Unclamped Nephron-Sparing Surgery: A Case Report. European Urology, 2011, 60, 591-594.	1.9	13
117	Laparoendoscopic Single-site Surgery in Urology: Worldwide Multi-institutional Analysis of 1076 Cases. European Urology, 2011, 60, 998-1005.	1.9	255
118	The influence of ejaculation and abstinence on urinary flow rates. Neurourology and Urodynamics, 2011, 30, 1571-1575.	1.5	4
119	Laparo-Endoscopic Single-Site Left Transperitoneal Adrenalectomy. European Urology, 2010, 57, 911-914.	1.9	45
120	Reply to Riccardo Autorino, Robert J. Stein and Jihad H. Kaouk's Letter to the Editor re: Luca Cindolo, Stefano Gidaro, Fabiola R. Tamburro, Luigi Schips. Laparo-Endoscopic Single-Site Left Transperitoneal Adrenalectomy. Eur Urol 2010;57:911–4. European Urology, 2010, 57, e48-e49.	1.9	1
121	Assessing Feasibility and Safety of Laparoendoscopic Single-Site Surgery Adrenalectomy: Initial Experience. Journal of Endourology, 2010, 24, 977-980.	2.1	24
122	CXCR4 and renal cancer: From lab to bedsideÂ. Cell Cycle, 2010, 9, 4785-4785.	2.6	1
123	Laparoendoscopic Single-Site Partial Nephrectomy Without Ischemia. Journal of Endourology, 2010, 24, 1997-2002.	2.1	25
124	Urological applications of N.O.T.E.S Surgical Oncology, 2009, 18, 153-156.	1.6	4
125	Editorial Comment on: Metastin Inhibits Migration and Invasion of Renal Cell Carcinoma with Overexpression of Metastin Receptor. European Urology, 2009, 55, 449-450.	1.9	1
126	Editorial Comment on: Single-Port Laparoscopic and Robotic Partial Nephrectomy. European Urology, 2009, 55, 1169-1170.	1.9	3

#	Article	IF	CITATIONS
127	Efficacy and safety of the haemostasis achieved by Vivostat system during laparoscopic partial nephrectomy. Archivio Italiano Di Urologia Andrologia, 2009, 81, 223-7.	0.8	8
128	Validation by calibration of the UCLA integrated staging system prognostic model for nonmetastatic renal cell carcinoma after nephrectomy. Cancer, 2008, 113, 65-71.	4.1	45
129	Prognostic variables to predict cancerâ€related death in incidental renal tumours. BJU International, 2008, 102, 1376-1380.	2.5	33
130	Case Report: Laparoscopic Removal of 10-cm Retroperitoneal Liposarcoma. Journal of Endourology, 2007, 21, 83-84.	2.1	13
131	A New Staging System for Locally Advanced (pT3–4) Renal Cell Carcinoma: A Multicenter European Study Including 2,000 Patients. Journal of Urology, 2007, 178, 418-424.	0.4	53
132	Prognostic Impact of Tumor Size on pT2 Renal Cell Carcinoma: An International Multicenter Experience. Journal of Urology, 2007, 178, 35-40.	0.4	56
133	The Use of Body Mass Index to Predict Pathological Stage in Patients with Clinically Localized Prostate Cancer. Oncology Research and Treatment, 2007, 30, 489-494.	1.2	1
134	Patients with renal cell carcinoma nodal metastases can be accurately identified: External validation of a new nomogram. International Journal of Cancer, 2007, 121, 2556-2561.	5.1	72
135	Unclassified renal cell carcinoma: an analysis of 85 cases. BJU International, 2007, 100, 802-808.	2.5	38
136	Patients with distant metastases from renal cell carcinoma can be accurately identified: external validation of a new nomogram. BJU International, 2007, 101, 071003001542001-???.	2.5	25
137	Serum Levels of Vascular Endothelial Growth Factor (VEGF) and Endostatin in Renal Cell Carcinoma Patients Compared to a Control Group. European Urology, 2007, 51, 168-174.	1.9	41
138	Relationship between Age at Diagnosis and Clinicopathologic Features of Renal Cell Carcinoma. European Urology, 2007, 51, 1298-1305.	1.9	100
139	Renal Cell Carcinoma with Nodal Metastases in the Absence of Distant Metastatic Disease: Prognostic Indicators of Disease-Specific Survival. European Urology, 2007, 51, 1616-1624.	1.9	93
140	Collecting Duct Renal Cell Carcinoma: A Matched Analysis of 41 Cases. European Urology, 2007, 52, 1140-1146.	1.9	88
141	Prognostic Relevance of Tumour Size in T3a Renal Cell Carcinoma: A Multicentre Experience. European Urology, 2007, 52, 155-162.	1.9	87
142	Autologous Fibrin Glue Using the Vivostat System for Hemostasis in Laparoscopic Partial Nephrectomy. European Urology, 2006, 50, 801-805.	1.9	36
143	SPARC Sling System for Treatment of Female Stress Urinary Incontinence in the Elderly. European Urology, 2006, 50, 826-831.	1.9	17
144	Multiinstitutional European validation of the 2002 TNM staging system in conventional and papillary localized renal cell carcinoma. Cancer, 2005, 104, 968-974.	4.1	82

#	Article	IF	Citations
145	Comparison of predictive accuracy of four prognostic models for nonmetastatic renal cell carcinoma after nephrectomy. Cancer, 2005, 104, 1362-1371.	4.1	207
146	Proposal for revision of the TNM classification system for renal cell carcinoma. Cancer, 2005, 104, 2116-2123.	4.1	72
147	Chromophobe renal cell carcinoma: Comprehensive analysis of 104 cases from multicenter European database. Urology, 2005, 65, 681-686.	1.0	60
148	Laparoscopic fenestration of lymphoceles after kidney transplantation with diaphanoscopic guidance. Urology, 2005, 66, 185-187.	1.0	11
149	Analysis of Insulin-Like Growth Factors and Insulin-Like Growth Factor I Receptor Expression in Renal Cell Carcinoma. American Journal of Clinical Pathology, 2004, 122, 931-937.	0.7	35
150	Expression of MUC1 (EMA) and E-cadherin in renal cell carcinoma: a systematic immunohistochemical analysis of 188 cases. Modern Pathology, 2004, 17, 180-188.	5.5	84
151	Keratin immunohistochemistry in renal cell carcinoma subtypes and renal oncocytomas: a systematic analysis of 233 tumors. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2004, 444, 127-134.	2.8	54
152	Does overweight impact on the prognosis of patients with renal cell carcinoma? A single center experience of 683 patients. Journal of Surgical Oncology, 2004, 88, 57-61.	1.7	39
153	Steroid Hormone Receptor Expression in Renal Cell Carcinoma: An Immunohistochemical Analysis of 182 Tumors. Journal of Urology, 2004, 171, 611-614.	0.4	88
154	Value of p53 as a prognostic marker in histologic subtypes of renal cell carcinoma: a systematic analysis of primary and metastatic tumor tissue. Urology, 2004, 63, 651-655.	1.0	91
155	Selenium levels of patients with newly diagnosed prostate cancer compared with control group. Urology, 2004, 63, 912-916.	1.0	31
156	Analysis of Insulin-like Growth Factors and Insulin-like Growth Factor I Receptor Expression in Renal Cell Carcinoma. American Journal of Clinical Pathology, 2004, 122, 931-937.	0.7	19
157	Do patients with a higher body mass index have a greater risk of advanced-stage renal cell carcinoma?. Urology, 2003, 62, 437-441.	1.0	14
158	Did the rate of incidental prostate cancer change in the era of PSA testing? A retrospective study of 1127 patients. Urology, 2003, 62, 451-455.	1.0	60
159	Detection of prostate cancer by TURP or open surgery in patients with previously negative transrectal prostate biopsies. Urology, 2003, 62, 883-887.	1.0	49
160	Impact of tumor-associated symptoms on the prognosis of patients with renal cell carcinoma: a single-center experience of 683 patients. Urology, 2003, 62, 1024-1028.	1.0	56
161	P63 Immunoreactivity Distinguishes Upper Urinary Tract Transitional-cell Carcinoma and Renal-cell Carcinoma Even in Poorly Differentiated Tumors. Journal of Histochemistry and Cytochemistry, 2003, 51, 1097-1099.	2.5	44
162	Findings and Clinical Course of a Localized Primitive Peripheral Neuroectodermal Tumor of the Kidney. Urologia Internationalis, 2003, 71, 319-321.	1.3	11

Luigi Schips

#	Article	IF	CITATIONS
163	Metastasis Of An Ascending Colon Carcinoma In The Prostate 10 Years After Hemicolectomy. Journal of Urology, 2002, 168, 641-641.	0.4	10
164	Is repeated transurethral resection justified in patients with newly diagnosed superficial bladder cancer?. Urology, 2002, 59, 220-223.	1.0	129